The European Medicines Agency has released recommendations on how Gilead Sciences’ investigational antiviral medicine remdesivir should be used via compassionate use programs to treat COVID-19 in the EU.
In two newly published documents, the agency explains the conditions under which early access to remdesivir could be given through compassionate use programs to patients with COVID‑19 who are not eligible for inclusion in clinical trials that are testing the product for coronavirus disease
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?